COVID Technology for Cancer; Biosimilars to Take Off; Bacteria-Based Therapies

— News, features, and commentary about cancer-related issues

MedpageToday
Cancer cells with OncoBreak in the center.

The mRNA-based vaccines for COVID-19 not only offer hope for bringing the pandemic under control but a glimpse into the future of new therapies for cancer and other chronic diseases. (Bloomberg)

Members of the American Society of Clinical Oncology elected Eric Winer, MD, of Dana-Farber Cancer Institute in Boston, as president for 2022-23.

The chemotherapy-free combination of pembrolizumab (Keytruda) and lenvatinib (Lenvima) improved overall survival, progression-free survival, and objective response rate in a phase III trial of advanced endometrial cancer, Merck announced.

The incidence of esophageal adenocarcinoma is increasing in people younger than 50. (American Association for Cancer Research)

Using ultrasound to pop microbubbles delivered to the liver may improve current radiation therapy strategies to treat liver cancer. (Jefferson Health)

After years of modest growth in the healthcare market, the biosimilars industry is poised for major expansion over the next five years. (Frost & Sullivan)

New and emerging therapies for the most common form of liver cancer will likely make significant inroads toward meeting some of the greatest unmet needs in the disease. (Global Data)

The bacterial makeup of the mouth (microbiome) might significantly influence the risk of lung cancer among nonsmokers. (Thorax)

Patients who opt for a "watch and wait" approach to minimally invasive treatment for rectal cancer may require only a few years of stringent follow-up. (Lancet Oncology)

Could a treatment originating from the "thunder god" help patients with pancreatic cancer? (TGen)

New recommendations for managing immune-related adverse events in patients treated with immunotherapeutic agents. (MD Anderson Cancer Center, Journal for Immunotherapy of Cancer)

A treatment containing fecal bacteria produced evidence of anticancer activity in patients with melanoma. (Science)

  • author['full_name']

    Charles Bankhead is senior editor for oncology and also covers urology, dermatology, and ophthalmology. He joined MedPage Today in 2007. Follow